arrow
I

Ian M. Adcock

imperial college london
H指数:126
被引数:6.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comorbidity Burden and Clinical Management Challenges in Severe Asthma: Insights from a Pan-European SHARP Study

重度哮喘的共病负担与临床管理挑战:来自泛欧洲SHARP研究的见解

2026-10-220
OAAI
Stool and Airway Microbiome Signatures Associated With Treatment Response to Dupilumab in Severe Asthma: Findings From the PRISM Study

严重哮喘患者对Dupilumab治疗反应相关的粪便和气道微生物组特征:PRISM研究的结果

2026-09-230
PRE
Improved peripheral airway reactance is associated with clinical remission following biologic therapy in severe asthma

生物制剂治疗后,外周气道反应性的改善与重症哮喘的临床缓解相关

2026-08-030
OAAI
The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma

2型细胞因子生物标志物高表达与低表达重症哮喘的气道转录组

2026-07-280
OAAI
Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma

哮喘持续时间较长与重症哮喘中升高的非T2痰生物标志物和降低的T2炎症相关

2026-07-280
OAAI
Clinical Features of Cellular Senescence Pathways in Severe Asthma

严重哮喘中细胞衰老通路临床特征

2026-06-180
OAAI
Circulating 1-Methylnicotinamide Predicts Dupilumab Response in Adult Asthma: A Prediction Model

1-甲基烟酰胺循环水平预测Dupilumab对成人哮喘的疗效:一项预测模型

2026-05-060
PRE
The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Utricaria, and Chronic Rhinosinusitis With Nasal Polyps

首个用于过敏领域的生物类似药:CT-P39(Omlyclo-Omalizumab-Igec)适用于哮喘、慢性自发性荨麻疹和伴有鼻息肉的慢性鼻窦炎

2026-04-250
PRE
The crucial role of normative ageing in respiratory pathogenesis

规范老化在呼吸系统病理发生中的关键作用

2026-04-240
OAAI
Nasal Airway Transcriptome Reflects Selected Asthma-Associated Gene Signatures in the Lower Airways

鼻腔气道转录组反映了与下气道相关的哮喘相关基因特征

2026-03-100
OA
Small Airways Dysfunction and Remission in Adults With Asthma: A Longitudinal Exploratory Analysis of the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Study

小气道功能障碍与哮喘成年患者的缓解:哮喘中小气道受累评估(ATLANTIS)研究的一项纵向探索性分析

2026-02-180
OA
Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules

慢性炎症性疾病中非生物和基于RNA的疗法的更新: 通过小分子的精准医学

2026-02-070
OAAI
Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registries

重症哮喘的多发病表型和相关特征: 欧洲重症哮喘登记处的一项观察性研究

2026-02-050
OAAI
The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways—An EAACI Position Paper

上气道炎症性疾病中嗅觉测试的未满足需求——EAACI立场文件

2026-02-020
PRE